key: cord-0900882-jz5wrhc4
authors: Garcia, Gustavo; Sharma, Arun; Ramaiah, Arunachalam; Sen, Chandani; Kohn, Donald; Gomperts, Brigitte; Svendsen, Clive N.; Damoiseaux, Robert D; Arumugaswami, Vaithilingaraja
title: Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication
date: 2020-06-25
journal: bioRxiv
DOI: 10.1101/2020.06.24.150326
sha: 76277cd78f877e52f3516be24661e73a6beec131
doc_id: 900882
cord_uid: jz5wrhc4

Emergence of a highly contagious novel coronavirus, SARS-CoV-2 that causes COVID-19, has precipitated the current global health crisis with over 479,000 deaths and more than 9.3 million confirmed cases. Currently, our knowledge of the mechanisms of COVID-19 disease pathogenesis is very limited which has hampered attempts to develop targeted antiviral strategies. Therefore, we urgently need an effective therapy for this unmet medical need. Viruses hijack and dysregulate cellular machineries in order for them to replicate and infect more cells. Thus, identifying and targeting dysregulated signaling pathways that have been taken over by viruses is one strategy for developing an effective antiviral therapy. We have developed a high-throughput drug screening system to identify potential antiviral drugs targeting SARS-CoV-2. We utilized a small molecule library of 430 protein kinase inhibitors, which are in various stages of clinical trials. Most of the tested kinase antagonists are ATP competitive inhibitors, a class of nucleoside analogs, which have been shown to have potent antiviral activity. From the primary screen, we have identified 34 compounds capable of inhibiting viral cytopathic effect in epithelial cells. Network of drug and protein relations showed that these compounds specifically targeted a limited number of cellular kinases. More importantly, we have identified mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA-Damage Response (DDR) pathways as key cellular signaling pathways critical for SARS-CoV-2 infection. Subsequently, a secondary screen confirmed compounds such as Berzosertib (VE-822), Vistusertib (AZD2014), and Nilotinib with anti SARS-CoV-2 activity. Finally, we found that Berzosertib, an ATR kinase inhibitor in the DDR pathway, demonstrated potent antiviral activity in a human epithelial cell line and human induced pluripotent stem cell (hIPSC)-derived cardiomyocytes. These inhibitors are already in clinical trials of phase 2 or 3 for cancer treatment, and can be repurposed as promising drug candidates for a host-directed therapy of SARS-CoV-2 infection. In conclusion, we have identified small molecule inhibitors exhibiting anti SARS-CoV-2 activity by blocking key cellular kinases, which gives insight on important mechanism of host-pathogen interaction. These compounds can be further evaluated for the treatment of COVID-19 patients following additional in vivo safety and efficacy studies. Disclosures None declared.

(hIPSC)-derived cardiomyocytes. These inhibitors are already in clinical trials of phase 2 or 3 for 23 cancer treatment, and can be repurposed as promising drug candidates for a host-directed 24 therapy of SARS-CoV-2 infection. In conclusion, we have identified small molecule inhibitors 25 exhibiting anti SARS-CoV-2 activity by blocking key cellular kinases, which gives insight on 26 important mechanism of host-pathogen interaction. These compounds can be further evaluated 27

for the treatment of COVID-19 patients following additional in vivo safety and efficacy studies. The current pandemic is caused by a newly discovered coronavirus, severe acute respiratory 3 syndrome-related coronavirus 2 (SARS-CoV-2). As of today, the disease has spread to 213 4 countries or territories, and the number of COVID-19 cases has surpassed 9.3 million globally, 5 with over 479,000 deaths 1,2 . SARS-CoV-2 is an enveloped single positive-sense RNA virus, which 6 codes a large non-structural polyprotein ORF1ab, four structural proteins and five accessory 7 proteins 3 . The virus enters into host cell by binding its transmembrane spike glycoprotein (S 8 protein) to the cellular membrane angiotensin converting enzyme 2 (ACE2) receptor 4 . ACE2 is 9 expressed in various organs, including lung, heart, kidney, and small intestine 4 . A recent study 10 showed a gradient of ACE2 expression in the respiratory tract with the highest levels in the nose 11 and decreasing expression in the lower respiratory tract 5 . In the proximal airway, SARS-CoV-2 12 infected ciliated cells, while type 2 alveolar cells (AT2) were found to be infected in the distal 13 airway 5 . The major causes of morbidity and mortality from COVID-19 are acute lung injury with 14 diffuse alveolar damage resulting in acute respiratory distress syndrome (ARDS) 6 . This results 15 from viral replication in lung epithelial cells causing cell injury, a vigorous immune response, 16 respiratory failure, and death. Moreover, there have been additional reports of patients exhibiting 17 acute kidney injury 7-9 , vascular inflammation (endotheliitis), and cardiac complications 10 . 18

Underlying cardiac ailments, diabetes, and obesity are linked to with increased risk of 19 mortality 11,12 . Developing a therapeutic that prevents viral replication is likely to significantly 20 reduce the severity of COVID-19 disease in affected individuals. 21

Our strategy for developing COVID-19 treatment is based on two main facts about the disease: 23 1) all patients presenting with symptoms have been infected with SARS-CoV-2 and the virus has 24 gained entry into the airway cells and spread systematically. Given the high affinity and potential 25 avidity in the viral Spike-cellular ACE2 receptor interaction, targeting the viral receptor to prevent 26 cell entry may not a viable strategy to treat patients with this infection, and 2) viruses are 27 dependent on cellular proteins for each step of their life cycle and they hijack many of the host 28 cell factors for their replication. Moreover, these host proteins are not subjected to evolutionary 29 pressure at the short duration of acute infection, therefore there is limited chance of emergence 30 , thus the kinases represent attractive targets for broad-spectrum therapy. These findings, 2 combined with the development and approval of a large number of kinase inhibitors for the 3 treatment of cancer 19 and inflammatory conditions 20 have sparked efforts aimed to determine the 4 therapeutic potential of such drugs to combat viral infections. 5 6 Currently approved antiviral drugs treat fewer than ten viral infections. The majority of these drugs 7 are direct-acting antivirals that target proteins encoded by individual viruses. As such, this 8 approach provides a narrow spectrum of coverage and therefore cannot address the large clinical 9

need. The high average cost (over two billion dollars) and long timeline (8-12 years) to develop 10 a new drug 21 , further limit the scalability of the DAA approach to drug development, particularly 11 with respect to emerging viruses. This approach is therefore not feasible for the short-term 12 development of a cure that is specific for SARS-CoV-2. The screening of approved drugs to 13 identify therapeutics for drug repurposing is therefore a valid and more universal approach, and 14 several approved drugs have been identified as having activity against many viral diseases 22-26 . 15 Previous drug screening of FDA approved compounds for SARS-CoV, MERS-CoV, and SARS-16

CoV-2 demonstrated the efficiency of screening approved or clinically developed drugs for 17 identification of potential therapeutic options for emerging viral diseases, which also provided an 18 expedited approach for supporting off-label use of approved therapeutics 26, 27 . 19

The objectives of this study are: 1) to identify small molecule kinase inhibitors with anti SARS-21

CoV-2 activity, and 2) to understand the mechanism of host-pathogen interactions by defining the 22 cellular signaling pathways critical for SARS-CoV-2 replication. 23

Infectious SARS-CoV-2 cell culture system. To identify antiviral compounds that could be used 27 for COVID-19 treatment, we established a SARS-CoV-2 infectious cell culture system and 28 virological assays using Vero-E6 cells. SARS-CoV-2, Isolate USA-WA1/2020, was obtained from 29 BEI Resources of National Institute of Allergy and Infectious Diseases (NIAID) and all studies 30 involving live virus was conducted in UCLA BSL3 high-containment facility. SARS-CoV-2 was 31 passaged once in Vero-E6 cells and viral stocks were aliquoted and stored at -80°C. Virus titer 32 was measured in Vero-E6 cells by TCID50 assay. Striking cytopathic effect (CPE) was observed 33 in SARS-CoV-2 infected cells ( Figure 1A) , indicating viral replication and associated cell injury. At 1 using SARS-CoV Spike (S) antibody. Spike protein was detected in the cytoplasm of the infected 2 cells, revealing presence of viral infection ( Figure 1B) . We also demonstrated that the drugs, 3 hydroxychloroquine (HQ; 10 µM), a known endosomal acidification inhibitor, as well as interferon-4 β effectively blocked SARS-CoV-2 infection 28 ( Figure 1C ). Therefore, we used this platform has 5 been used for the subsequent drug screening studies. 6 7 High throughput drug screen of Kinase inhibitors. Next, we set out to evaluate the antiviral 8

property of cellular protein kinase inhibitors. A step by step workflow of our drug screen is provided 9

in Figure 2A . The drug compound library was selected to broadly cover kinase inhibitors and the 10 screening concentration was identified that would have optimal activity and minimal toxicity. We 11 tested a set of 430 kinase inhibitors that have typically been tested for oncologic and immunologic 12

indications and which also have Phase 1/2/3 data available (Supplementary Table 1 ). However, 13 data for these compounds are not available on SARS-CoV-2. Since this kinase inhibitor library is 14 targeting cancer indications, we decided to avoid using human lung cancer epithelial cell lines. We used an immunofluorescent assay to quantify viral infected cells from each well. This Serine/threonine-protein kinase ATR (ataxia telangiectasia and Rad3-related protein) which can 2 inhibit the DNA Damage Response pathway. Previous studies have shown that Berzosertib 3 blocks the phosphorylation of downstream signaling factor CHK1 (phospho-CHK1-S345) and 4 potentiates phosphorylation of H2AX (phospho-H2AX-S139 or γH2AX) marker by DNA damaging 5 agents 33,34 . It has been known that many viruses hijack this pathway for efficient replication 35,36 . 6

One of the mode of actions could be inhibition of the aberrant activation of DNA repair signaling 7 pathway by the virus, which can result in virus replication blockage. Indeed, we observed that Interestingly, we have observed that several antiviral compounds targeted mTOR-PI3K-AKT 23 pathway, including AZD2014 and Torin2 ( Figure 2B ). The mammalian target of rapamycin 24

(mTOR) regulates cell growth, autophagy, and various metabolic processes 37 We identified a lead drug Berzosertib, which acts as an antiviral agent against SARS-CoV-2 by 33 limiting viral genomic RNA replication. Berzosertib is a selective inhibitor of ATR kinase, which has been previously shown to block the DNA damage response pathway in cancer cells, with no 1 discernable effect on normal cells 44 . The DNA damage response pathway is responsible for 2 maintaining cellular genome integrity which is also modulated by DNA tumor viruses 45 were cultured in EMEM growth media containing 10% fetal bovine serum (FBS) and penicillin 28 (100 units/ml). ACE2 entry receptor overexpressing human embryonic kidney 293T cells (293T-29 ACE2) were established and cultured in the media described above with the presence of 30 puromycin (1 µg/ml). Cells were incubated at 37°C with 5% CO2. The hiPSC-CMs were generated 31 from hiPSCs by directed differentiation approach modulating Wnt signaling using a small-32 molecule 48 and as previously described 48 , cardiomyocytes were metabolically selected by using 33 glucose deprivation. After selection, hiPSC-CMs were replated for viral infection. immunostained with anti-dsRNA antibody (J2 clone; Absolute Antibody Inc, USA) to assess viral 30 genome replication ( Figure 1C) . 31 and permeabilized using blocking buffer (0.3% Triton X-100, 2% BSA, 5% Goat Serum, 5% 1 Donkey Serum in 1 X PBS) for 1 hour at room temperature. For immunostaining, cells were 2 incubated overnight at 4℃ with each primary antibody. The cells were then washed with 1X PBS 3 three times and incubated with respective secondary antibody for 1 hour at room temperature. 4

Nuclei were stained with DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) (Life 5 Technologies) at a dilution of 1:5000 in 1 X PBS. Image acquisition was done using Leica DM 6 IRB fluorescent microscopes. 7 8 Western Blot analysis. Cells were lysed in 50 mM Tris pH 7.4, 1% NP-40, 0.25% sodium 9 deoxycholate, 1 mM EDTA, 150 mM NaCl, 1 mM Na3VO4, 20 Mm or NaF, 1mM PMSF, 2 mg ml -10 1 aprotinin, 2 mg ml -1 leupeptin and 0.7 mg ml -1 pepstatin or Laemmli Sample Buffer (Bio Rad, 11

Hercules, CA). Cell lysates were resolved by SDS-PAGE using 10% gradient gels and transferred 12 to a 0.2 µm PVDF membrane. Subsequently, the membranes were blocked with 5% skim milk 

Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways 3 Critical for SARS-CoV-2 Replication

Supplementary Table 1. List of 430 kinase inhibitors used in this study

Supplementary Video 2. SARS-CoV-2 infected hiPSC-CM beats (3 dpi)

Supplementary Video 3. Remdesivir (10µM) treated and SARS-CoV-2 infected hiPSC-CM beats

Hydroxychloroquine (10µM) treated and SARS-CoV-2

Supplementary Video 5. Berzosertib (250 nM) pre-treated and SARS-CoV-2

Supplementary Video 6. Berzosertib (250 nM) post-treated and SARS-CoV-2